BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

304 related articles for article (PubMed ID: 20855960)

  • 1. Inhibition of MCL-1 in breast cancer cells promotes cell death in vitro and in vivo.
    Mitchell C; Yacoub A; Hossein H; Martin AP; Bareford MD; Eulitt P; Yang C; Nephew KP; Dent P
    Cancer Biol Ther; 2010 Nov; 10(9):903-17. PubMed ID: 20855960
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CDK inhibitors upregulate BH3-only proteins to sensitize human myeloma cells to BH3 mimetic therapies.
    Chen S; Dai Y; Pei XY; Myers J; Wang L; Kramer LB; Garnett M; Schwartz DM; Su F; Simmons GL; Richey JD; Larsen DG; Dent P; Orlowski RZ; Grant S
    Cancer Res; 2012 Aug; 72(16):4225-37. PubMed ID: 22693249
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.
    Chen S; Dai Y; Harada H; Dent P; Grant S
    Cancer Res; 2007 Jan; 67(2):782-91. PubMed ID: 17234790
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy.
    Martin AP; Mitchell C; Rahmani M; Nephew KP; Grant S; Dent P
    Cancer Biol Ther; 2009 Nov; 8(21):2084-96. PubMed ID: 19823038
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lapatinib and obatoclax kill tumor cells through blockade of ERBB1/3/4 and through inhibition of BCL-XL and MCL-1.
    Cruickshanks N; Hamed HA; Bareford MD; Poklepovic A; Fisher PB; Grant S; Dent P
    Mol Pharmacol; 2012 May; 81(5):748-58. PubMed ID: 22357666
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors restore toxic BH3 domain protein expression in anoikis-resistant mammary and brain cancer stem cells, thereby enhancing the response to anti-ERBB1/ERBB2 therapy.
    Cruickshanks N; Hamed HA; Booth L; Tavallai S; Syed J; Sajithlal GB; Grant S; Poklepovic A; Dent P
    Cancer Biol Ther; 2013 Oct; 14(10):982-96. PubMed ID: 24025251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extrinsic pathway- and cathepsin-dependent induction of mitochondrial dysfunction are essential for synergistic flavopiridol and vorinostat lethality in breast cancer cells.
    Mitchell C; Park MA; Zhang G; Yacoub A; Curiel DT; Fisher PB; Roberts JD; Grant S; Dent P
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3101-12. PubMed ID: 18065490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obatoclax interacts synergistically with the irreversible proteasome inhibitor carfilzomib in GC- and ABC-DLBCL cells in vitro and in vivo.
    Dasmahapatra G; Lembersky D; Son MP; Patel H; Peterson D; Attkisson E; Fisher RI; Friedberg JW; Dent P; Grant S
    Mol Cancer Ther; 2012 May; 11(5):1122-32. PubMed ID: 22411899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lapatinib resistance in HCT116 cells is mediated by elevated MCL-1 expression and decreased BAK activation and not by ERBB receptor kinase mutation.
    Martin AP; Miller A; Emad L; Rahmani M; Walker T; Mitchell C; Hagan MP; Park MA; Yacoub A; Fisher PB; Grant S; Dent P
    Mol Pharmacol; 2008 Sep; 74(3):807-22. PubMed ID: 18544666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells.
    Booth L; Roberts JL; Avogadri-Connors F; Cutler RE; Lalani AS; Poklepovic A; Dent P
    Cancer Biol Ther; 2018 Mar; 19(3):239-247. PubMed ID: 29333953
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paclitaxel-induced apoptosis is BAK-dependent, but BAX and BIM-independent in breast tumor.
    Miller AV; Hicks MA; Nakajima W; Richardson AC; Windle JJ; Harada H
    PLoS One; 2013; 8(4):e60685. PubMed ID: 23577147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lapatinib and obatoclax kill breast cancer cells through reactive oxygen species-dependent endoplasmic reticulum stress.
    Cruickshanks N; Tang Y; Booth L; Hamed H; Grant S; Dent P
    Mol Pharmacol; 2012 Dec; 82(6):1217-29. PubMed ID: 22989520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis.
    Nguyen M; Marcellus RC; Roulston A; Watson M; Serfass L; Murthy Madiraju SR; Goulet D; Viallet J; BĂ©lec L; Billot X; Acoca S; Purisima E; Wiegmans A; Cluse L; Johnstone RW; Beauparlant P; Shore GC
    Proc Natl Acad Sci U S A; 2007 Dec; 104(49):19512-7. PubMed ID: 18040043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obatoclax and lapatinib interact to induce toxic autophagy through NOXA.
    Tang Y; Hamed HA; Cruickshanks N; Fisher PB; Grant S; Dent P
    Mol Pharmacol; 2012 Apr; 81(4):527-40. PubMed ID: 22219388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Obatoclax is a direct and potent antagonist of membrane-restricted Mcl-1 and is synthetic lethal with treatment that induces Bim.
    Nguyen M; Cencic R; Ertel F; Bernier C; Pelletier J; Roulston A; Silvius JR; Shore GC
    BMC Cancer; 2015 Aug; 15():568. PubMed ID: 26231047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. OSU-03012 interacts with lapatinib to kill brain cancer cells.
    Booth L; Cruickshanks N; Ridder T; Chen CS; Grant S; Dent P
    Cancer Biol Ther; 2012 Dec; 13(14):1501-11. PubMed ID: 22990204
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells.
    Huang S; Okumura K; Sinicrope FA
    Clin Cancer Res; 2009 Jan; 15(1):150-9. PubMed ID: 19118042
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of Bcl-2 antiapoptotic members by obatoclax potently enhances sorafenib-induced apoptosis in human myeloid leukemia cells through a Bim-dependent process.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Blood; 2012 Jun; 119(25):6089-98. PubMed ID: 22446485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human melanoma cells under endoplasmic reticulum stress are more susceptible to apoptosis induced by the BH3 mimetic obatoclax.
    Jiang CC; Wroblewski D; Yang F; Hersey P; Zhang XD
    Neoplasia; 2009 Sep; 11(9):945-55. PubMed ID: 19724688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obatoclax induces Atg7-dependent autophagy independent of beclin-1 and BAX/BAK.
    McCoy F; Hurwitz J; McTavish N; Paul I; Barnes C; O'Hagan B; Odrzywol K; Murray J; Longley D; McKerr G; Fennell DA
    Cell Death Dis; 2010 Dec; 1(12):e108. PubMed ID: 21368880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.